Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Aneja
Arun Pal Aneja, Digvijaygram IN
| Patent application number | Description | Published |
|---|---|---|
| 20110300768 | ETHYLENE ADSORBENT PACKAGING OR BARRIER MATERIAL AND METHOD OF MAKING THE SAME - An ethylene adsorbent packaging or barrier material and method of making the same. The package or barrier comprises a textile substrate impregnated with a solution of zeolite, cross-linker and binder. The method of making the ethylene adsorbent packaging or barrier material comprises impregnating a textile substrate with a solution of zeolite powder with crosslinker and binder in a solvent at a PH of 5.0 to 7.0 adjusted with an organic acid followed by removing the excess solution from the substrate and drying and curing the substrate at 50-250° C. If desired the substrate is formed to the desired shape. The packaging can be used for packing ethylene susceptible and perishable articles. The barrier material can be used as a barrier or as a separator for ethylene gas. | 12-08-2011 |
Arun Pal Aneja, Greenville, NC US
| Patent application number | Description | Published |
|---|---|---|
| 20090260707 | Woven Textile Fabric with Cotton/Microdenier Filament Bundle Blend - A fabric includes warp and weft yarns interwoven in a series of repeat units. In the fabric, the warp yarns comprise cotton yarns and the weft yarns comprise microdenier filament bundles. Such a fabric can provide desirable tactile properties for articles such as sheets, pillowcases, blankets and the like. | 10-22-2009 |
Jonathan Paul Aneja, Kirkland, WA US
| Patent application number | Description | Published |
|---|---|---|
| 20080320453 | TYPE INFERENCE AND LATE BINDING - A type inference option is available for a computer programming language. The option acts as a switch to specify whether or not type inference is applicable (e.g., on or off). Type inference can be employed in conjunction with late binding or options therefor. In this manner, a computer program can be developed with the convenience of type inference and the flexibility of late binding while still maintaining at a degree of type safety. | 12-25-2008 |
| 20100218173 | IMPLICIT LINE CONTINUATION - Modified compilers and other development tools provide implied line continuation within a sequence of syntax tokens of a programming language grammar which includes multiple semantic contexts and which uses line termination as presumptive statement termination. When source code parsing encounters a line terminator adjacent a context-dependent implicit line continuation token in an associated semantic context, an explicit decision is made whether to imply line continuation. Line continuation may also be implied in response to other specified tokens. | 08-26-2010 |
Karan Aneja, Los Angeles, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20090087891 | METHODS AND DEVICE FOR PRODUCING HYDROGEN FROM BIOMASS - Disclosed herein are methods of producing molecular hydrogen, where the methods comprise contacting a solution comprising urea with a urease to produce ammonia, and contacting the ammonia with a first catalyst to produce a first gaseous mixture comprising molecular hydrogen. | 04-02-2009 |
Mansi Aneja, Delhi IN
| Patent application number | Description | Published |
|---|---|---|
| 20090170603 | Sports community commentary - Live sports community commentary technology operable to provide viewers with live sports commentary, and provide commentators with a means to provide commentary to viewers is disclosed. The live sports community commentary technology presents commentary from commentators on a sports event to viewers of the sports event, and provides feedback, motivation, and incentives to the commentators. | 07-02-2009 |
Rajindra Aneja, Ithaca, NY US
| Patent application number | Description | Published |
|---|---|---|
| 20110040108 | INOSITOLPHOSPHOLIPIDS AND ANALOGUES PHOSPHATIDYLINOSITOL PRODUCTS AND PROCESSES - Embodiments of the invention relate to natural and synthetic inositolphospholipid (IPL) materials, their preparation and applications. They provide compositions of the parent IPL comprising phosphatidylinositol (PI), PI-phosphates (phosphoinositides) and derivatives and analogues, and a process for their production starting from natural IPL. The embodiments further provide functional derivatives of PI for biomedical applications including a platform for drug design and delivery to therapeutic targets in the phosphoinositide mediated cellular signaling and allied cascades. The embodiments pertain to IPL having absolute stereo-structure. The embodiments further pertain to unique IPL and PI product compositions for defined applications, particularly pharmaceutical compositions for prophylaxis and treatment of diseases related to aberrant cellular and nuclear signaling mediated by PI and PI derived phosphates, and associated phosphoinositide specific enzymes including PI-PLC and PI 3-kinase. | 02-17-2011 |
Rakesh Aneja, Farmington Hills, MI US
| Patent application number | Description | Published |
|---|---|---|
| 20080314033 | Treatment of diesel engine exhaust - A diesel exhaust treatment system for treating exhaust gas from a diesel engine comprises at least one diesel particulate filter, at least one diesel exhaust fluid mixing chamber and at least one selective catalytic reduction converter (SCR). In one desirable embodiment, plural diesel particulate filters are arranged in parallel and plural SCRs are arranged in parallel. These components including the diesel exhaust fluid mixing chamber can be included in a common housing with the exhaust flow reversing directions a plurality of times as it passes through the treatment system from an exhaust inlet to an exhaust outlet. The housing can be coupled to one vehicle frame rail with most of the housing and components contained therein positioned outside the outer surface of the one frame rail. | 12-25-2008 |
Ritu Aneja, Lilburn, GA US
| Patent application number | Description | Published |
|---|---|---|
| 20100227878 | NOSCAPINE ANALOGS AND THEIR USE IN TREATING CANCERS, INCLUDING DRUG-RESISTANT CANCERS - Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are noscapine analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers. While the antitussive plant alkaloid, noscapine, binds tubulin, displays anticancer activity, and has a safe pharmacological profile in humans, structure-function analyses pointed to a proton at position 9 of the isoquinoline ring that can be modified without compromising tubulin binding activity. Noscapine analogs with various functional moieties at position 9 on the isoquinoline ring kill human cancer cells resistant to other anti-microtubule agents, such as vincas and taxanes. Representative analogs include the 9-nitro, 9-bromo-, 9-iodo-, and 9-fluoro-noscapines, which bind tubulin and induce apoptosis selectively in tumor cells (ovarian and T-cell lymphoma) resistant to paclitaxel, vinblastine and teniposide. Surprisingly, treatment with one of the analogs, 9-nitro-nos, at doses as high as 100 μM, did not affect the cell cycle profile of normal human fibroblasts. This selectivity for cancer cells represents a unique edge over the other available antimitotics. The compounds can perturb the progression of cell cycle by mitotic arrest, followed by apoptotic cell death associated with increased caspase-3 activation and appearance of TUNEL-positive cells. Thus, the compounds are novel therapeutic agents for a variety of cancers, including ovarian and T-cell lymphoma cancers, even those that have become drug-resistant to currently available chemotherapeutic drugs. | 09-09-2010 |
| 20110286919 | CONJUGATES OF NOSCAPINE AND FOLIC ACID AND THEIR USE IN TREATING CANCER - The present invention is directed to compounds which are conjugates of two non-toxic natural products, noscapine (and various noscapine analogs) and folic acid (and various folic acid analogs), where the folic acid is conjugated to noscapine or the noscapine analog at the 9-position on the isoquinoline ring on the noscapine framework. Pharmaceutical compositions including the compounds, and methods of treating various tumors using the compounds and compositions, are also disclosed. The conjugates are particularly useful for treating cancers which overexpress the Folate Receptor α (FRa) receptor. | 11-24-2011 |
| 20110294844 | 9-AMINONOSCAPINE AND ITS USE IN TREATING CANCERS, INCLUDING DRUG-RESISTANT CANCERS - 9-aminonoscapine, prodrugs thereof, and pharmaceutically acceptable salts thereof, are disclosed. Pharmaceutical compositions including 9-aminonoscapine, and methods of preparation and use thereof are disclosed. 9-aminonoscapine is a noscapine analog that can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, by binding tubulin and inducing apoptosis selectively in tumor cells (ovarian and T-cell lymphoma) resistant to paclitaxel, vinblastine and teniposide. 9-aminonoscapine can perturb the progression of cell cycle by mitotic arrest, followed by apoptotic cell death associated with increased caspase-3 activation and appearance of TUNEL-positive cells. Thus, 9-aminonoscapine is a novel therapeutic agents for a variety of cancers, including ovarian and T-cell lymphoma cancers, even those that have become drug-resistant to currently available chemotherapeutic drugs. | 12-01-2011 |